These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from Dec. 14 through Dec. 20, 2023. Source: VerityData
Increases in Holdings
Liquidia
Caligan Partners raised its interest in the cardiopulmonary-disease-focused pharmaceutical firm to 10,360,945 shares. That figure excludes shares tied to founder David Johnson, who serves on Liquidia’s board. Caligan acquired 1,117,318 Liquidia shares through a Dec. 14 offering that priced the shares at $7.16 each.
Following the offering’s close, Caligan owns 15.1% of Liquidia’s outstanding stock. So far this year, Liquidia stock has gained nearly 68%.
Decreases in Holdings
Janus International Group
Clearlake Capital liquidated its stake in the commercial door and self-storage unit maker. On Dec. 14, Clearlake Capital sold 23,044,110 Janus International shares at a price of $10.01 each as settlement for a post-paid-forward transaction. Clearlake Capital sold 26,548 Janus International shares on the open market on Dec. 15 at prices of $11.83 to $11.87 apiece. Outside of 15,306 restricted units held by Clearlake Capital founder Jose Feliciano, chairman of Janus International, Clearlake is no longer a shareholder in the industrial firm.
Shares of Janus International have gained almost 29% year to date.
Peabody Energy
Elliott Management continued to shed its interest in the coal producer, down to 14,975,000 shares. Elliott sold 2,975,000 Peabody Energy shares from Dec. 6 through Dec. 15 at prices of $23.35 to $23.94 each. That followed Elliott’s sale of 3,159,807 shares of the coal company at similar prices from mid-November through Dec. 1. Elliott now holds 11.4% of Peabody Energy’s outstanding shares. The stock has lost about 7.1% this year.
Disc Medicine
OrbiMed Advisors cut its position in the clinical-stage pharmaceutical firm to 1,702,237 shares. OrbiMed sold 567,400 Disc Medicine shares from Dec. 12 through Dec. 14 at per share prices of $56.75 to $60.16. OrbiMed now owns 7.1% of the pharmaceutical company’s tradable stock.
So far this year, Disc Medicine stock has gained roughly 187%, boosted by progress in its drug pipeline. Advances include the FDA’s fast track of its treatment for polycythemia vera, a blood cancer, in September, and this month, Disc’s presentation of results of its Phase 2 trial for bitopertin, a treatment for rare metabolic disorder erythropoietic protoporphyria.
Blue Bird
ASP BB Holdings slashed its stake in the bus manufacturing company to 4,042,650 shares. ASP sold 2.5 million Blue Bird shares through a Dec. 19 offering that priced the shares at $25.10 apiece. ASP previously sold 1,262,500 shares through a September 2023 offering priced at $21 per share. That followed a June 2023 offering for the sale of 1,725,000 shares at $20 apiece. After the latest offering, ASP owns 12.6% of Blue Bird’s outstanding stock.
So far this year, Blue Bird stock has gained roughly 140%.
Email: [email protected]
Read the full article here
